Search Result

Results for "

alpha-synuclein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (51) Amyloid-β (5) Apoptosis (4) Autophagy (8) Beclin1 (3) Biochemical Assay Reagents (1) Caspase (1) Cholinesterase (ChE) (1) DNA/RNA Synthesis (3) DYRK (2) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (4) Fungal (2) Huntingtin (1) Interleukin Related (2) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) Lactate Dehydrogenase (1) Lipoxygenase (1) Monoamine Oxidase (1) Necroptosis (1) NOD-like Receptor (NLR) (1) Nuclear Hormone Receptor 4A/NR4A (1) Opioid Receptor (1) Phosphatase (1) Prolyl Endopeptidase (PREP) (1) PROTACs (3) Proteasome (1) Reactive Oxygen Species (3) RIP kinase (1) Sirtuin (1) Tau Protein (1) TNF Receptor (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (72)

By Targets:

α-synuclein (51)

Amyloid-β (5)

Apoptosis (4)

Autophagy (8)

Beclin1 (3)

Biochemical Assay Reagents (1)

Caspase (1)

Cholinesterase (ChE) (1)

DNA/RNA Synthesis (3)

DYRK (2)

E3 Ligase Ligand-Linker Conjugates (1)

Endogenous Metabolite (4)

Fungal (2)

Huntingtin (1)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

Keap1-Nrf2 (1)

Lactate Dehydrogenase (1)

Lipoxygenase (1)

Monoamine Oxidase (1)

Necroptosis (1)

NOD-like Receptor (NLR) (1)

Nuclear Hormone Receptor 4A/NR4A (1)

Opioid Receptor (1)

Phosphatase (1)

Prolyl Endopeptidase (PREP) (1)

PROTACs (3)

Proteasome (1)

Reactive Oxygen Species (3)

RIP kinase (1)

Sirtuin (1)

Tau Protein (1)

TNF Receptor (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (72)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

(Rac)-Minzasolmin (Rac)-UCB0599; NPT200-11	α-synuclein	Neurological Disease
(Rac)-Minzasolmin ((Rac)-UCB0599) is a brain penetrating inhibitor of accumulation of *alpha-synuclein* (ASYN) misfolding and aggregation. (Rac)-Minzasolmin can be used for research of Parkinson's disease .

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

α-Synuclein inhibitor 9	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an *α-Synuclein* inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

*tau Protein/α-synuclein-IN-1*	α-synuclein	Neurological Disease
tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and *α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein*-IN-1 can be used in study Alzheimer’s disease .

α-Synuclein inhibitor 8	α-synuclein	Neurological Disease
α-Synuclein inhibitor 8 is an active inhibitor of *α-Synuclein* with an IC₅₀ value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .

α-Synuclein (67-78) (human)	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

α-Synuclein inhibitor 3	Others	Neurological Disease
α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .

*Dyrk1A/α-synuclein-IN-2*	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

α-Synuclein modulator 1	α-synuclein	Neurological Disease
α-Synuclein modulator 1 (Compound 7k) is a modulator for *α-synuclein. α-Synuclein* modulator 1 exhibits a maximal absorption and emission wavelength of 386 and 603 nm in ACN/PBS (1:1) buffer .

*tau Protein/α-synuclein-IN-2*	Amyloid-β α-synuclein	Neurological Disease
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and *α-syn* inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces *α-syn* oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

*PROTAC α-synuclein* degrader 3**	PROTACs α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 3 (compound 5) is a potent and selective PROTAC α-synuclein degrader. PROTAC α-synuclein degrader 3 can be used in research of Parkinson's disease .

α-Synuclein inhibitor 13	α-synuclein	Neurological Disease
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .

α-Synuclein inhibitor 11	α-synuclein	Neurological Disease
α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .

α-Synuclein inhibitor 12	α-synuclein	Neurological Disease
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of *α-Syn* (α-synuclein) aggregation and can be used in the study of neurological diseases .

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

*Dyrk1A/α-synuclein-IN-1*	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

*PROTAC α-synuclein* degrader 5**	PROTACs α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 5 is a highly selective small-molecule degraders (PROTAC) of *α-synuclein* aggregates, with an DC₅₀ of 7.51 μM and the highest degradation rate D_max of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research .

α-Synuclein inhibitor 10	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

α-Synuclein aggregate binder 1	α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease .

Minzasolmin UCB0599; (R)-NPT200-11	α-synuclein	Neurological Disease
Minzasolmin is an alpha-synuclein oligomerization inhibitor .

α-Synuclein inhibitor 7	Others	Neurological Disease
α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.95 μM and inhibition ratio at 30 μM of 85.8% .

α-Synuclein inhibitor 4	Others	Neurological Disease
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 0.98 μM and inhibition ratio at 30 μM of 91.2% .

α-Synuclein inhibitor 5	α-synuclein	Neurological Disease
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.22 μM and inhibition ratio at 30 μM of 94.3% .

α-Synuclein inhibitor 6	Others	Neurological Disease
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.70 μM and inhibition ratio at 30 μM of 94.4% .

*PROTAC α-synuclein* degrader 6**	PROTACs α-synuclein Tau Protein	Neurological Disease
PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader of *α-synuclein* and tau, with EC₅₀ of 1.57 μM and 4.09 μM, respectively. PROTAC α-synuclein degrader 6 plays an important role in neurodegenerative diseases (NDs) research (Blue:ubiquitin E3 ligase cereblon ligand (HY-14658), Black: linker (HY-128803); Pink: Ligand for target protein (HY-151035)) .

AGK7 SIRT2 Inhibitor,Inactive Control	Sirtuin	Neurological Disease
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .

Cinpanemab BIIB054; Anti-alpha-synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

PDpep1.3	α-synuclein	Others Neurological Disease
Pdpe 1.3 is a peptide inhibitor, The main activity is to destroy the direct interaction between *α-synuclein* and CHarged Multivesicular body Protein 2B (CHMP2B). By interfering with this interaction, PDpep1.3 restores the degradation function of the endocytosomes and lysosomes, thereby reducing alpha-synuclein levels and protecting dopaminergic neurons from alpha-synuclein mediated degradation. Pdpe 1.3 can be used in the study of neurodegenerative diseases and protein-protein interactions .

Corynoxine	Autophagy	Neurological Disease Cancer
Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

Corynoxine hydrochloride	Autophagy	Neurological Disease Cancer
Corynoxine hydrochloride, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria macrophylla. Corynoxine hydrochloride is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an α-synuclein knockdown peptide. Tat-βsyn-degron binds toα-synuclein and reduces α-synuclein levels in primary rat cortical neuron cultures. Tat-βsyn-degron also reduces α-synuclein levels and decreases the parkinsonian toxin-induced neuronal damage and motor impairment in a mouse toxicity model of PD .

Dopal	Endogenous Metabolite Reactive Oxygen Species α-synuclein	Neurological Disease
Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species, and triggers aggregation of *α-synuclein. DOPAL elicits α-synuclein* accumulation and hampers α-synuclein clearance in primary neurons .

Aerophobin-2	α-synuclein	Neurological Disease
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

Sycosterol A	α-synuclein	Neurological Disease
Sycosterol A is an **α-synuclein (α-syn)** inhibitory sterol .

FTY720-C2	Others	Neurological Disease
FTY720-C2 is a derivative of FTY72 (HY-12005). FTY720-C2 promotes the expression of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in multiple system atrophy (MSA) models, without causing immunosuppression. FTY720-C2 improves motor dysfunction and reduces the levels of insoluble alpha-synuclein (αSyn) in MSA mouse models. FTY720-C2 is blood-brain barrier penetrate .

ELN484228	α-synuclein	Neurological Disease
ELN484228 is a blocker of *α-synuclein* which is a key protein in Parkinson’s disease.

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

(S)-Minzasolmin (S)-UCB0599; (S)-NPT200-11	α-synuclein	Neurological Disease
(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

1,570 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,570 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Cat. No.	Product Name	Target	Research Area

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P5044

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5046

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-P5043

α-Synuclein (67-78) (human)	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
Pdpe 1.3 is a peptide inhibitor, The main activity is to destroy the direct interaction between *α-synuclein* and CHarged Multivesicular body Protein 2B (CHMP2B). By interfering with this interaction, PDpep1.3 restores the degradation function of the endocytosomes and lysosomes, thereby reducing alpha-synuclein levels and protecting dopaminergic neurons from alpha-synuclein mediated degradation. Pdpe 1.3 can be used in the study of neurodegenerative diseases and protein-protein interactions .

HY-P5106

α-Synuclein (32-37) (human)	Peptides	Others
α-Synuclein (32-37) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an α-synuclein knockdown peptide. Tat-βsyn-degron binds toα-synuclein and reduces α-synuclein levels in primary rat cortical neuron cultures. Tat-βsyn-degron also reduces α-synuclein levels and decreases the parkinsonian toxin-induced neuronal damage and motor impairment in a mouse toxicity model of PD .

Cat. No.	Product Name	Target	Research Area

HY-P99356

Cinpanemab BIIB054; Anti-alpha-synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

HY-P99405

Prasinezumab PRX 002; RG 7935; RO 7046015	α-synuclein	Neurological Disease
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated *α-synuclein*. Prasinezumab has the potential for Parkinson's disease research .

Species:	Human (2) Mouse (1)
Tag:	His (1) Tag Free (2)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P70660

	SNCA Protein, Mouse alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca	Mouse	E. coli
	SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free.

HY-P70577

	SNCA Protein, Human alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human is the recombinant human-derived SNCA protein, expressed by E. coli , with tag free.

HY-P71327

	SNCA Protein, Human (His) alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (His) is the recombinant human-derived SNCA protein, expressed by E. coli , with N-6*His labeled tag. The total length of SNCA Protein, Human (His) is 140 a.a., with molecular weight of ~18.0 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-Y0790S

Cuminaldehyde-d8
Cuminaldehyde-d8 is deuterated labeled Cuminaldehyde (HY-Y0790). Cuminaldehyde is the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. Cuminaldehyde shows anticancer activity .

HY-W015307S

4-Ethyloctanoic acid-13C2
4-Ethyloctanoic acid- ¹³C₂ is ¹³C labeled Cuminaldehyde (HY-Y0790). Cuminaldehyde is the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. Cuminaldehyde shows anticancer activity .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82328

	alpha Synuclein Antibody (YA2073) SNCA; NACP; PARK1; alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, IP	Human, Rat
	alpha Synuclein Antibody (YA2073) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2073), targeting alpha Synuclein, with a predicted molecular weight of 14 kDa (observed band size: 18 kDa). alpha Synuclein Antibody (YA2073) can be used for WB, IHC-P, IP experiment in human, rat background.

HY-P81739

	*Phospho-alpha Synuclein* (Ser129) Antibody (YA1484)** SNCA; NACP; PARK1; alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, ICC/IF	Human, Mouse, Rat
	Phospho-alpha Synuclein (Ser129) Antibody (YA1484) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1484), targeting Phospho-alpha Synuclein (Ser129), with a predicted molecular weight of 14 kDa. Phospho-alpha Synuclein (Ser129) Antibody (YA1484) can be used for WB, ICC/IF experiment in human, mouse, rat background.

HY-P83254

	alpha/beta Synuclein Antibody (YA2999) alpha synuclein; beta synuclein; NACP; PD1; SNCA; SNCB	WB, ICC/IF, FC	Human, Mouse, Rat
	alpha/beta Synuclein Antibody (YA2999) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2999), targeting alpha/beta Synuclein, with a predicted molecular weight of 14 kDa (observed band size: 18 kDa). alpha/beta Synuclein Antibody (YA2999) can be used for WB, ICC/IF, FC experiment in human, mouse, rat background.